Home > > > Macular Degeneration Treatment Market Size, Share, Growth Insights & Forecast 2026–2034

Macular Degeneration Treatment Market Size, Share, Growth Insights & Forecast 2026–2034

Author : Mahesh Chavan | Published On : 01 Jul 2026

The global Macular Degeneration Treatment Market is witnessing strong growth due to the increasing prevalence of age-related macular degeneration (AMD), expanding geriatric population, and continuous advancements in retinal disease therapies. According to the latest market analysis, the market was valued at USD 16.7 billion in 2025 and is projected to reach USD 33.88 billion by 2034, expanding at a CAGR of 8.18% during the forecast period. Growing investments in ophthalmic research, the introduction of innovative biologics, and improved access to specialized eye care are expected to accelerate market expansion over the coming years.

  • Market Size (2025): USD 16.7 Billion
  • Market Size (2026): USD 18.07 Billion
  • CAGR (2026–2034): 8.18%
  • Forecast Year: 2034
  • Projected Market Size (2034): USD 33.88 Billion
  • Dominant Region: North America
  • Fastest Growing Region: Europe

Growing Burden of Retinal Disorders Fuels Market Expansion

The rising incidence of retinal diseases, particularly age-related macular degeneration, continues to drive demand for advanced treatment options worldwide. AMD remains one of the leading causes of irreversible vision loss among individuals aged 50 years and above. As the global elderly population increases, healthcare providers are witnessing a significant rise in patients requiring long-term retinal care and vision preservation therapies.

Improved awareness regarding early diagnosis and timely treatment has further strengthened demand for anti-VEGF therapies, nutritional supplements, laser procedures, and emerging regenerative treatment approaches.

Increasing Research Investments Accelerate Therapeutic Innovation

Pharmaceutical companies and biotechnology firms are investing heavily in research and development to introduce next-generation therapies for macular degeneration. Scientists continue to explore gene therapies, stem cell-based treatments, retinal pigment epithelial cell transplantation, and long-acting biologics aimed at slowing disease progression and improving patient outcomes.

Growing collaborations between research institutes, healthcare organizations, and industry leaders are expected to enhance treatment accessibility while expanding the global product pipeline.

Rising Aging Population Creates Significant Growth Opportunities

Population aging remains one of the strongest long-term growth drivers for the macular degeneration treatment market. As life expectancy increases globally, the number of individuals vulnerable to age-related eye diseases continues to rise.

Healthcare systems across developed and emerging economies are increasing investments in ophthalmology services, digital eye care technologies, and advanced diagnostic solutions to address the growing patient burden. Innovations such as AI-assisted retinal imaging and precision medicine are also expected to support future market development.

Limited Public Awareness Continues to Challenge Market Growth

Despite improvements in treatment availability, limited awareness regarding AMD symptoms and early diagnosis continues to restrict market growth in several developing regions. Many patients seek medical attention only after experiencing significant vision loss, reducing treatment effectiveness.

Increasing public health campaigns, routine eye examinations, and educational initiatives are expected to improve early detection rates and encourage timely intervention.

Wet Age-Related Macular Degeneration Holds the Largest Market Share

Based on type, the wet age-related macular degeneration segment dominates the global market owing to its severe impact on vision and greater dependence on pharmaceutical treatment. Anti-VEGF injections remain the standard of care for wet AMD and continue to generate substantial market revenue.

Meanwhile, the dry AMD segment is expected to witness steady growth as ongoing research introduces novel therapeutic approaches targeting disease progression before advanced vision impairment occurs.

Late-Stage AMD Represents the Leading Disease Stage

Among disease stages, late-stage AMD accounts for the largest market share due to the high demand for advanced therapies and continuous monitoring. Patients diagnosed with geographic atrophy or neovascular AMD often require specialized treatment and long-term clinical management.

The increasing availability of innovative therapies under clinical development is expected to improve treatment outcomes and expand market opportunities throughout the forecast period.

Intravitreal Administration Remains the Preferred Treatment Route

The intravitreal route of administration continues to dominate the market because it enables direct drug delivery to the retina while minimizing systemic side effects. Anti-VEGF therapies administered through intravitreal injections have become the standard treatment for neovascular AMD, offering improved visual outcomes and disease control.

Continued advancements in sustained-release drug delivery systems are expected to reduce treatment frequency and improve patient compliance.

Hospitals Continue to Lead Sales Channel Segment

Hospitals remain the primary treatment centers for macular degeneration due to their specialized ophthalmology departments, advanced diagnostic equipment, and experienced retinal specialists. Increasing availability of minimally invasive procedures and comprehensive patient management supports hospital segment growth.

At the same time, ambulatory surgical centers are gaining popularity by providing convenient outpatient retinal procedures with reduced healthcare costs.

North America Maintains Market Leadership

North America continues to dominate the global macular degeneration treatment market, supported by advanced healthcare infrastructure, high awareness levels, favorable reimbursement systems, and strong presence of leading pharmaceutical companies. The United States remains the largest contributor owing to rising AMD prevalence and continuous product innovation.

Europe Emerges as the Fastest Growing Regional Market

Europe is projected to register the fastest growth throughout the forecast period. Rising healthcare investments, increasing elderly population, government-supported ophthalmic research, and improved access to advanced retinal treatments are accelerating market expansion across countries including France, Germany, and the United Kingdom.

Asia-Pacific Shows Strong Future Growth Potential

Asia-Pacific is expected to experience significant market growth driven by increasing healthcare expenditure, improving awareness of retinal diseases, and rapidly aging populations in countries such as Japan, China, South Korea, and India. Ongoing clinical research and expanding healthcare infrastructure continue to create favorable opportunities for market participants.

Competitive Landscape

The global macular degeneration treatment market remains highly competitive, with leading pharmaceutical and biotechnology companies focusing on product innovation, strategic collaborations, clinical research, and regulatory approvals to strengthen their market positions.

Major companies operating in the market include:

  • Novartis AG
  • Pfizer Inc.
  • PanOptica
  • Bausch Health Companies Inc.
  • Regeneron Pharmaceuticals Inc.
  • Aerie Pharmaceuticals Inc.
  • REGENXBIO Inc.
  • Bayer AG

Recent Industry Developments

  • In August 2022, Novartis announced plans to spin off its Sandoz division into an independent company, allowing greater strategic focus on innovative medicines.
  • In September 2022, Bayer highlighted new clinical findings related to Kerendia while continuing to strengthen its research capabilities across multiple therapeutic areas, including ophthalmology.

Click to Download and Read the Full Report: https://straitsresearch.com/report/macular-degeneration-treatment-market

Market Outlook

The global macular degeneration treatment market is expected to maintain strong momentum through 2034 as the prevalence of AMD rises alongside global aging demographics. Continuous innovation in retinal therapeutics, expanding research investments, improved diagnostic technologies, and increasing healthcare awareness are anticipated to support sustainable market growth. As pharmaceutical companies continue developing next-generation biologics, gene therapies, and regenerative treatments, the market is likely to witness significant transformation, creating new opportunities for healthcare providers, investors, and industry stakeholders worldwide.